Autres langues Merck & Co., Inc.

Actions

MRK

US58933Y1055

Temps réel estimé Cboe BZX Autres places de cotation 21:42:53 09/05/2024			Varia. 5j.	Varia. 1 janv.
130,4 ^USD	+0,63 %		+1,63 %	+19,57 %

16:44	Merck dit que Santé Canada approuve la combinaison Keytruda dans le carcinome des voies biliaires	MT
15:21	Mise à jour sectorielle : Les actions du secteur de la santé sont stables avant la cloche jeudi	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Merck Says Health Canada Approve Keytruda Combination in Biliary Tract Carcinoma	16:44
Sector Update: Health Care Stocks Steady Pre-Bell Thursday	15:21
MÄRKTE USA/Weiter wenig Bewegung - Arm sehr schwach	15:00
Merck : échec d'un essai dans le cancer de l'endomètre	14:32
Merck Study of Keytruda With Chemotherapy in Endometrial Cancer Fails to Meet Endpoint	14:16
Merck's Late-Stage Study for Cancer Drug Keytruda Plus Chemotherapy Fails to Meet Primary Endpoint	13:37
Merck : succès de l'initiative 'Merck for Mothers'	13:15
Health Canada Approves KEYTRUDA® for adult patients with locally advanced unresectable or metastatic biliary tract carcinoma, in combination with gemcitabine-based chemotherapy	13:05
Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative Intent	12:46
AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents	08/05
AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents	08/05
AstraZeneca, Merck Sue Over Alleged Cancer Drug Patents Infringement	08/05
AstraZeneca, Merck Sue Over Cancer Drug Patent Infringement	08/05
Merck Expands Access to High-Quality Maternal Care for More Than 30 Million Women Worldwide Through Merck for Mothers	08/05
Merck to Participate in the Bank of America Securities 2024 Healthcare Conference	08/05
CytomX Therapeutics, Inc. Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with Keytruda® (pembrolizumab)	07/05
Merck : résultats encourageants dans le cancer gastrique	02/05
Merck Says Keytruda Meets Primary Endpoint in Late-Stage Gastric Cancer Trial	01/05
Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma	01/05
Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival as First-Line Treatment in Patients with HER2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma	01/05

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

A la une

Merck & Co., Inc. : Une vache à lait qui cache des vedettes

Le 11 juillet 2022 à 11:12